PBMWWPsyence Biomedical Ltd. Warrant
0.0300USDMkt Cap: —P/E: —3d ago
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in…
Industry Peers
Healthcare$1.12TUSDP/E 42.2
$651.25BUSDP/E 31.4
$468.22BUSDP/E 75.1
$345.19BUSDP/E 24.7
$376.37BUSDP/E 122.0
$350.16BUSDP/E 25.1
$283.47BUSDP/E 22.7
$276.41BUSDP/E 23.7
$301.95BUSDP/E 24.0
$234.02BUSDP/E 25.0
$257.42BUSDP/E 24.8
$240.45BUSDP/E 24.5
$237.11BUSDP/E 27.0
$232.67BUSDP/E 33.9
$206.69BUSDP/E 11.5
$203.17BUSDP/E 37.7
$181.18BUSD
$159.99BUSDP/E 36.9
$153.85BUSDP/E 39.0
$138.82BUSDP/E 31.9
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-6.94M $
Revenue/Share—
Last Price0.0300 USD
Fiscal Year End—
MR Quarter—
Employees12
CountryUS
SectorHealthcare
Industry—
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.00
EPS (TTM)—
EPS (Forward)—
52W Range
0.0258100% of range0.0300
52W High0.0300 USD
52W Low0.0258 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-40.94%
ROA-39.48%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.14M $
CapEx (TTM)500.23K $
FCF Margin—
FCF Yield—
Net Debt-7.44M $
Net Debt/EBITDA1.19
Balance Sheet
Debt/Equity—
Current Ratio14.62
Quick Ratio12.12
Book Value/Sh7.389 USD
Cash/Share1.952 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float2.61M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta1.67
S&P 52W Chg21.00%
Avg Vol (30d)12.00K
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—